| Website | hmplglobal.com |
| Category | BioTech |
| Phone | +86 21 5079 0088 |
| Employees |
| TOTAL | $20.2M |
| VENTURE FUNDING TOTAL | $20.2M |
| Venture Round, 11/10 Mitsui & Co | $12.5M |
| Venture Round, 12/10 SBCVC Fund III Company | $7.7M |
Hutchison MediPharma is an internationally focused novel pharmaceutical company focused on discovering, developing and commercializing innovative therapeutics in oncology and autoimmune diseases. Its pipeline includes clinical and preclinical therapeutics for cancer and autoimmune diseases. Products include a novel oral compound for Inflammatory Bowel Diseases, which is entering Phase III for UC (Ulcerative Colitis) in the US & Europe; a novel first-in-class IL-10 modulating inflammation compound that completed phase I in Australia; and two other NCEs in oncology at or entering Phase I this year in China. Well over a dozen NCEs are in preclinical development.
